Antiretroviral drugs and therapy (ART)

Management of Buruli Ulcer–HIV Coinfection - Technical Update

- Released in

Areas of Africa endemic for Buruli ulcer (BU), caused by Mycobacterium ulcerans, also have a high prevalence of human immunodeficiency virus (HIV), with adult prevalence rates between 1% and 5%. However, there is limited information on the prevalence of BU–HIV coinfection. Preliminary evidence suggests that HIV infection may increase the risk of BU disease. In the Médecins Sans Frontières project in Akonolinga, Cameroon, HIV prevalence was approximately 3–6 times higher among BU patients than the regional estimated HIV prevalence.

Surveillance of Antiretroviral Toxicity: Global HIV, Hepatitis and STIs Programme: What's New in Person-centred HIV Patient and Antiretroviral Drug Toxicity Monitoring

- Released in

In April 2020, new directions in global guidance for HIV strategic information and treatment monitoring were updated. This technical update outlines the key developments with respect to recommended indicators and approaches and tools for monitoring antiretroviral drug toxicity with the purpose of strengthening country implementation and ensuring the safe use of antiretroviral drugs.

Considerations for Introducing New Antiretroviral Drug Formulations for Children

- Released in

This policy brief is for country-level programme managers, technical advisers and procurement bodies involved in the process of procuring, introducing and scaling up optimal antiretroviral therapy for infants and young children living with HIV in low and middle-income countries. With multiple new antiretroviral drug options and the availability of new evidence, antiretroviral therapy for children is a dynamic and rapidly evolving space.

Start Free Stay Free AIDS Free - 2020 Report

- Released in

This progress report reviews recent gains, new developments and remaining challenges as countries approach the 2020 targets of the Start Free Stay Free AIDS Free framework.

HIV Drug Resistance Surveillance Guidance: 2015 Update

- Released in
This update provides an overview of the essential elements that programme managers should include in programme planning to prevent and monitor the emergence of HIV drug resistance (HIVDR). It also describes programmatic relevance and use of data.

Factsheet 6: HIV care and Antiretroviral Therapy (ART) Services in Nepal, as of July 2015

- Released in

Background about ART program in Nepal:
- ART was started in Nepal in February 2004 from Sukraraj Tropical and infectious Hospital, Teku.
- ART is available for free of cost for all eligible people living with HIV (PLHIV).
- Currently ART is available from 61 sites in 55 districts. HIV care is available from many sites including ART sites.
- National Consolidated Guideline for Treating and Preventing HIV in Nepal 2014 is the guiding document for providing HIV treatment and care in Nepal.
- CD4 count service is available from 27 sites across the country.

Guidelines for the Clinical Management of HIV Infection in Myanmar (Fourth Edition)

- Released in
This update will both augment and complement the 2011 Myanmar Guidelines published by the National AIDS Programme. In Myanmar, a country with limited resources and capacity, the available resources must be best employed to achieve the best possible solutions for People Living with HIV. With this in mind, evidence based recommendations have also been made in PMTCT; PEP and coinfection with HBV and HCV.